Y-mAbs Therapeutics, Inc.
YMAB
$5.11
$0.030.59%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -30.31% | -38.45% | -23.76% | 36.99% | 70.68% |
| Total Depreciation and Amortization | -37.22% | -27.21% | -26.12% | -25.64% | -13.80% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 20.29% | 29.35% | -7.79% | -22.59% | -55.69% |
| Change in Net Operating Assets | 28.94% | 81.51% | 50.05% | 93.29% | 52.67% |
| Cash from Operations | -8.89% | 42.30% | 21.46% | 72.56% | 72.57% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 457.70% | 4,211.00% | -- | 4,603.85% | 1,223.08% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 457.70% | 4,211.00% | -- | 4,603.85% | 1,223.08% |
| Foreign Exchange rate Adjustments | -105.88% | -100.00% | 106.12% | 107.41% | 162.96% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 8.54% | 57.96% | 34.00% | 77.92% | 73.66% |